Protein Synthesis Inhibitor Antibiotics

Protein-synthesis inhibitors are antibacterial drugs that target the bacterial ribosome, exploiting the structural differences between the bacterial 70S ribosome and the eukaryotic 80S ribosome to block translation selectively. The group spans several chemically distinct classes — macrolides, tetracyclines, aminoglycosides, chloramphenicol, and the oxazolidinones — that bind different sites on the ribosomal subunits.

Definition

Protein-synthesis inhibitor antibiotics are antibacterial agents that bind the bacterial ribosome (the 30S or 50S subunit) and interrupt one or more steps of translation, thereby halting bacterial protein production.

Scope

The entry covers the ribosomal targets of the major protein-synthesis-inhibiting classes, the distinction between agents that bind the 30S and the 50S subunit, and the principal resistance routes of ribosomal target modification, enzymatic drug inactivation, and efflux. It is a reference and educational topic within bacteriology, not prescribing guidance.

Core questions

• Which ribosomal subunit and step of translation does each class target?
• How does selective toxicity arise from differences between bacterial and human ribosomes?
• Which classes are bacteriostatic and which can be bactericidal?
• What are the main resistance mechanisms — target modification, drug inactivation, and efflux?

Key concepts

• Bacterial 70S ribosome (30S and 50S subunits)
• Macrolides and the 50S binding site
• Tetracyclines and the 30S A-site
• Aminoglycosides and translational mistranslation
• Oxazolidinones and initiation-complex inhibition
• Ribosomal RNA methylation (erm-mediated resistance)
• Ribosomal protection proteins and drug efflux

Mechanisms

These drugs act at distinct ribosomal sites. Macrolides bind the 50S subunit near the nascent-peptide exit tunnel and stall elongation; tetracyclines bind the 30S subunit and block aminoacyl-tRNA from the A-site; aminoglycosides bind the 30S subunit and cause mistranslation; chloramphenicol inhibits 50S peptidyl transferase; and oxazolidinones interfere with formation of the initiation complex. Most are bacteriostatic, though aminoglycosides are bactericidal. Resistance follows a few recurring patterns: modification of the ribosomal target (for example erm-encoded methylation of 23S rRNA that reduces macrolide binding), enzymatic inactivation of the drug (as with aminoglycoside-modifying enzymes), ribosomal protection proteins, and active efflux (Grossman, 2016; Blair et al., 2015; Alekshun & Levy, 2007).

Clinical relevance

Protein-synthesis inhibitors are important options against many Gram-positive and atypical pathogens, and resistance to them — particularly macrolide and tetracycline resistance — shapes laboratory reporting and surveillance. This entry describes the pharmacological mechanisms for orientation and study and does not provide treatment or dosing recommendations.

Epidemiology

Resistance determinants for this group, such as erm methylases and tetracycline efflux and protection genes, are frequently carried on mobile genetic elements and are widespread among staphylococci, streptococci, and enteric bacteria (Grossman, 2016; Tong et al., 2015).

History

Streptomycin, the first aminoglycoside, and chloramphenicol emerged in the 1940s, followed by the tetracyclines and macrolides, broadening the spectrum of available antibacterials. The oxazolidinones, introduced clinically around 2000, were the first wholly new ribosome-targeting class in decades and were developed in part to address resistance among Gram-positive organisms (Grossman, 2016; Tong et al., 2015).

Key figures

• Stuart B. Levy
• Trudy H. Grossman
• Laura J. V. Piddock

Seminal works

• grossman-2016
• alekshun-levy-2007

Frequently asked questions

Why do protein-synthesis inhibitors harm bacteria but spare human cells?

They bind the bacterial 70S ribosome, which differs structurally from the human 80S ribosome, so they can block bacterial translation with comparatively limited effect on host protein synthesis.

Are these antibiotics bactericidal or bacteriostatic?

Most ribosome-targeting classes such as macrolides, tetracyclines, and chloramphenicol are bacteriostatic, meaning they inhibit growth, whereas aminoglycosides are typically bactericidal.